Algert Global LLC Buys 93,429 Shares of Privia Health Group, Inc. (NASDAQ:PRVA)

Algert Global LLC lifted its holdings in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 639.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,048 shares of the company's stock after acquiring an additional 93,429 shares during the quarter. Algert Global LLC owned approximately 0.09% of Privia Health Group worth $2,112,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Alyeska Investment Group L.P. increased its stake in shares of Privia Health Group by 20.0% in the fourth quarter. Alyeska Investment Group L.P. now owns 300,000 shares of the company's stock valued at $5,865,000 after buying an additional 50,000 shares in the last quarter. Northern Trust Corp grew its holdings in Privia Health Group by 14.2% during the 4th quarter. Northern Trust Corp now owns 1,392,641 shares of the company's stock worth $27,226,000 after acquiring an additional 173,563 shares during the last quarter. Tudor Investment Corp ET AL raised its stake in shares of Privia Health Group by 16.5% in the fourth quarter. Tudor Investment Corp ET AL now owns 267,899 shares of the company's stock worth $5,237,000 after acquiring an additional 37,904 shares during the last quarter. Two Sigma Securities LLC acquired a new position in shares of Privia Health Group during the fourth quarter worth approximately $463,000. Finally, Voya Investment Management LLC lifted its position in shares of Privia Health Group by 4.7% during the fourth quarter. Voya Investment Management LLC now owns 212,342 shares of the company's stock worth $4,151,000 after purchasing an additional 9,539 shares in the last quarter. 94.48% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Privia Health Group

In related news, CFO David Mountcastle sold 3,445 shares of the business's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total value of $80,371.85. Following the completion of the sale, the chief financial officer now directly owns 176,231 shares in the company, valued at $4,111,469.23. The trade was a 1.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Parth Mehrotra sold 15,100 shares of the stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total value of $352,283.00. Following the transaction, the chief executive officer now owns 454,281 shares in the company, valued at $10,598,375.73. The trade was a 3.22% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,484 shares of company stock valued at $799,163 in the last three months. 10.70% of the stock is currently owned by company insiders.

Privia Health Group Stock Up 1.5%

Shares of PRVA traded up $0.37 during trading hours on Wednesday, hitting $24.67. The company had a trading volume of 204,932 shares, compared to its average volume of 764,884. The business has a fifty day moving average of $23.35 and a 200-day moving average of $22.40. The firm has a market cap of $2.99 billion, a price-to-earnings ratio of 246.72, a PEG ratio of 3.47 and a beta of 0.87. Privia Health Group, Inc. has a 12 month low of $15.92 and a 12 month high of $26.09.

Analyst Ratings Changes

Several research firms recently issued reports on PRVA. Canaccord Genuity Group raised their price target on Privia Health Group from $29.00 to $30.00 and gave the company a "buy" rating in a report on Friday, February 28th. Truist Financial raised their target price on shares of Privia Health Group from $27.00 to $28.00 and gave the company a "buy" rating in a research note on Thursday, April 10th. JMP Securities reiterated a "market outperform" rating and set a $29.00 price target on shares of Privia Health Group in a research report on Monday, April 28th. Barclays increased their price objective on shares of Privia Health Group from $21.00 to $23.00 and gave the company an "equal weight" rating in a report on Thursday, April 10th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $30.00 target price on shares of Privia Health Group in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $27.38.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.